Chinese pharma firms led by Kelun are moving fast to develop the next-generation of cytotoxic "warheads," a key component of antibody-drug conjugates, disclosed company executives at conference in Suzhou.

Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

The recent partnerships on Claudin 18.2-targeting agents between Chinese biotechs and big pharma have brought China innovation to a new phase that Chinese firms can be proud of, an executive from Keymed Biosciences, one of the Chinese biotechs involved in such deals, tells Scrip in an interview.